Stay updated on Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page.

Latest updates to the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedPublication entry for SERENA-2 (Lancet Oncol. 2024) and its erratum added; the entry revision updated from v3.4.2 to v3.4.3 to reflect this change.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check31 days agoChange Detected- Page revision updated from v3.4.1 to v3.4.2. No substantive changes to core study details were observed.SummaryDifference0.0%

- Check38 days agoChange DetectedThe page shows a revision update from v3.4.0 to v3.4.1, with no visible changes to study information.SummaryDifference0.0%

- Check53 days agoChange DetectedThe updates are minor UI and metadata adjustments, including a glossary option being shown, updates to Last Update Submitted that Met QC Criteria and Last Update Posted, and the revision label updated to v3.4.0.SummaryDifference0.1%

- Check59 days agoChange DetectedSystem revision updated from v3.3.3 to v3.3.4; no changes to study details, eligibility criteria, or results are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check88 days agoChange DetectedLocations section updated with new sites (Alabama, California, Florida, Nebraska, Ohio, Tennessee, Wisconsin, and Quebec) and removal of existing sites. Revision: v3.3.3.SummaryDifference0.5%

Stay in the know with updates to Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page.